文献リスト

1) 日本臨床腎移植学会. 腎移植臨床登録集計報告(2007)-3 2006年経過追跡調査結果. 移植. 2007; 42: 545-57

2) Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000; 23: 101-13

3) Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005; 80: S254-64

4) Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370: 59-67

5) 今西正昭, 国方聖司, 秋山隆弘, 他. 当科における腎移植後の悪性腫瘍7例の検討及び本邦における腎移植後の悪性腫瘍の統計. 移植. 1996; 31: 100-7

6) Sheil AG, Disney AP, Mathew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc. 1993; 25: 1383-4

7) 野島道生. 腎移植後の悪性腫瘍とPTLD アンケートによる症例調査とスクリーニングの状況. 今日の移植. 2008; 21: 279-84

8) Kauffman HM, Cherikh WS, McBride MA, et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int. 2006; 19: 607-20

9) Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004; 4: 905-13

10) Webster AC, Craig JC, Simpson JM, et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15, 183 recipients. Am J Transplant. 2007; 7: 2140-51

11) Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351: 623-8

12) Imao T, Ichimaru N, Takahara S, et al. Risk factors for malignancy in Japanese renal transplant recipients. Cancer. 2007; 109: 2109-15

13) Kauffman HM. Malignancies in organ transplant recipients. J Surg Oncol. 2006; 94: 431-3

14) Myron Kauffman H, McBride MA, Cherikh WS, et al. Transplant tumor registry: donor related malignancies. Transplantation. 2002; 74: 358-62

15) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 6. 1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant. 2002; 17 Suppl 4: 31-3, 5-6

16) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 6. 3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant. 2002; 17 Suppl 4: 32, 4-6

17) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 6. 2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. Nephrol Dial Transplant. 2002; 17 Suppl 4: 31-6

18) Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000; 11 Suppl 15: S1-86

19) Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997; 2: 14-7

20) Woodle ES, Gupta M, Buell JF, et al. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc. 2005; 37: 958-9

21) Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant. 2002; 6: 456-64

22) Wigle DA, Chaparro C, Humar A, et al. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation. 2001; 72: 1783-6

23) Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995; 20: 1346-53

24) Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol. 2009; 24: 731-6

25) Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005; 80: 1233-43

26) Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999; 397: 530-4

27) Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 2003; 76: 597-602

28) Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005; 331: 810

29) Sorensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004; 96: 709-11

30) Karagas MR, Cushing GL Jr, Greenberg ER, et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer. 2001; 85: 683-6

31) Yu J, Lemas V, Page T, et al. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase. Cancer Res. 1989; 49: 5555-60

32) Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer. 2005; 5: 4

33) Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004; 4: 222-30

34) Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975; 28: 727-32

35) Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997; 64: 36-42

36) Dennis PB, Fumagalli S, Thomas G. Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev. 1999; 9: 49-54

37) Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs. 2002; 11: 1845-57

38) Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005; 23: 5347-56

39) Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006; 12: 5165-73

40) Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81

41) Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003; 63: 4472-80

42) Garcia VD, Bonamigo-Filho JS, Neumann J, et al. Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases. Transplant Proc. 2002; 34: 2993-5

43) Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003; 75: 1710-7

44) Al-Akash SI, Al Makadma AS, Al Omari MG. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant. 2005; 9: 249-53

45) Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005; 352: 1317-23

46) Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 2004; 10: 1301-11

47) Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 2005; 80: 749-58

48) Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87: 233-42

49) Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003; 349: 847-58

50) Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005; 5: 2521-30

51) Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005; 80: 244-52

52) Chapman TM, Perry CM. Everolimus. Drugs. 2004; 64: 861-72; discussion 73-4

53) Orentas RJ, Schauer DW Jr, Ellis FW, et al. Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant. 2003; 7: 305-14

54) Rowe DT, Webber S, Schauer EM, et al. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001; 3: 79-87

55) Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005; 5: 2894-900

56) Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant. 2006; 6: 1906-12

57) Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol. 1998; 20: 343-55

58) Pirsch JD, Stratta RJ, Sollinger HW, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med. 1989; 86: 241-4

59) Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation. 2000; 69: 827-33

60) Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007; 86: 599-607

61) Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence？ Clin J Am Soc Nephrol. 2008; 3 Suppl 2: S87-S100

62) Kanaan N, Goffin E. Multiple bilateral fibroadenomas of the breasts requiring mastectomy in a renal transplant patient. Clin Nephrol. 2004; 61: 151-4

63) LeBrun CJ, Diehl LF, Abbott KC, et al. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis. 2000; 35: 237-43

64) Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant. 2003; 3: 619-25

65) Wong G, Howard K, Craig JC, et al. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Transplantation. 2008; 85: 532-41

66) 日本泌尿器科学会, 編. 腎癌診療ガイドライン2007年版. 金原出版; 2007: p. 14-6

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp